

Rita Shaknovich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11292588/publications.pdf>

Version: 2024-02-01

80
papers

7,128
citations

81900

39
h-index

95266

68
g-index

82
all docs

82
docs citations

82
times ranked

10292
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA. <i>Clinical Cancer Research</i> , 2021, 27, 4221-4229.	7.0	61
2	The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice. <i>Cancers</i> , 2021, 13, 3501.	3.7	50
3	Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. <i>Annals of Oncology</i> , 2020, 31, 745-759.	1.2	770
4	Histone demethylase LSD1 is required for germinal center formation and BCL6-driven lymphomagenesis. <i>Nature Immunology</i> , 2019, 20, 86-96.	14.5	71
5	SOX11 augments BCR signaling to drive MCL-like tumor development. <i>Blood</i> , 2018, 131, 2247-2255.	1.4	37
6	AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis. <i>Nature Communications</i> , 2018, 9, 222.	12.8	51
7	TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis. <i>Cancer Discovery</i> , 2018, 8, 1632-1653.	9.4	120
8	Extracellular vesicles in DLBCL provide abundant clues to aberrant transcriptional programming and genomic alterations. <i>Blood</i> , 2018, 132, e13-e23.	1.4	23
9	The new frontier of epigenetic heterogeneity in B-cell neoplasms. <i>Current Opinion in Hematology</i> , 2017, 24, 402-408.	2.5	11
10	<i>CREBBP</i> Inactivation Promotes the Development of HDAC3-Dependent Lymphomas. <i>Cancer Discovery</i> , 2017, 7, 38-53.	9.4	218
11	EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis. <i>Cancer Cell</i> , 2016, 30, 197-213.	16.8	200
12	Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. <i>Journal of Clinical Investigation</i> , 2016, 126, 3351-3362.	8.2	133
13	<i>Crebbp</i> Mutations Disrupt Dynamic Enhancer Acetylation in B-Cells, Enabling HDAC3 to Drive Lymphomagenesis. <i>Blood</i> , 2016, 128, 735-735.	1.4	0
14	Signatures of accelerated somatic evolution in gene promoters in multiple cancer types. <i>Nucleic Acids Research</i> , 2015, 43, 5307-5317.	14.5	28
15	TET1 is a tumor suppressor of hematopoietic malignancy. <i>Nature Immunology</i> , 2015, 16, 653-662.	14.5	173
16	Epigenomic evolution in diffuse large B-cell lymphomas. <i>Nature Communications</i> , 2015, 6, 6921.	12.8	111
17	DNA Methylation Dynamics of Germinal Center B Cells Are Mediated by AID. <i>Cell Reports</i> , 2015, 12, 2086-2098.	6.4	87
18	The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. <i>Nature Medicine</i> , 2015, 21, 1199-1208.	30.7	359

#	ARTICLE	IF	CITATIONS
19	Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma. <i>Journal of Clinical Investigation</i> , 2015, 125, 4559-4571.	8.2	37
20	SOX11 Cooperates with CCND1 in Mantle Cell Lymphoma Pathogenesis. <i>Blood</i> , 2015, 126, 1253-1253.	1.4	1
21	A Chromatin Reader That Acts As a Key to Lock in and Coordinate Recruitment of Transcription Factors and a Novel Polycomb Complex to Bivalent Chromatin Thus Driving Formation of Germinal Centers and B-Cell Lymphomas. <i>Blood</i> , 2015, 126, 434-434.	1.4	0
22	Down-Regulation of eIF4GII by miR-520c-3p Represses Diffuse Large B Cell Lymphoma Development. <i>PLoS Genetics</i> , 2014, 10, e1004105.	3.5	39
23	Epigenetic Function of Activation-Induced Cytidine Deaminase and Its Link to Lymphomagenesis. <i>Frontiers in Immunology</i> , 2014, 5, 642.	4.8	25
24	CTCF Haploinsufficiency Destabilizes DNA Methylation and Predisposes to Cancer. <i>Cell Reports</i> , 2014, 7, 1020-1029.	6.4	154
25	Epigenetic diversity in hematopoietic neoplasms. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 477-484.	7.4	11
26	Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. <i>Blood</i> , 2014, 123, 1699-1708.	1.4	83
27	Characterization of DLBCL-Derived Exosomes and Investigation of Their Biological Properties. <i>Blood</i> , 2014, 124, 3021-3021.	1.4	8
28	Demethylase Activity of Aid during Germinal Center B Cell Maturation Could Contribute to Lymphomagenesis. <i>Blood</i> , 2014, 124, 59-59.	1.4	1
29	Mirna-181a expression Lead to Longer Animal Survival and Slower Tumor-Growth Rate in Diffuse Large B-Cell Lymphoma Xenograft Models. <i>Blood</i> , 2014, 124, 2963-2963.	1.4	0
30	EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation. <i>Cancer Cell</i> , 2013, 23, 677-692.	16.8	706
31	Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma. <i>Cancer Discovery</i> , 2013, 3, 1002-1019.	9.4	180
32	Aberration in DNA Methylation in B-Cell Lymphomas Has a Complex Origin and Increases with Disease Severity. <i>PLoS Genetics</i> , 2013, 9, e1003137.	3.5	102
33	Gene Expression and Epigenetic Deregulation. <i>Advances in Experimental Medicine and Biology</i> , 2013, 792, 133-150.	1.6	5
34	Downregulation of FOXP1 is required during germinal center B-cell function. <i>Blood</i> , 2013, 121, 4311-4320.	1.4	62
35	Mechanisms of epigenetic deregulation in lymphoid neoplasms. <i>Blood</i> , 2013, 121, 4271-4279.	1.4	32
36	EZH2 and BCL6 Cooperate To Create The Germinal Center B-Cell Phenotype and Induce Lymphomas Through Formation and Repression Of Bivalent Chromatin Domains. <i>Blood</i> , 2013, 122, 1-1.	1.4	23

#	ARTICLE	IF	CITATIONS
37	Epigenomic Evolution In Diffuse Large B-Cell Lymphomas. <i>Blood</i> , 2013, 122, 634-634.	1.4	2
38	GobyWeb: Simplified Management and Analysis of Gene Expression and DNA Methylation Sequencing Data. <i>PLoS ONE</i> , 2013, 8, e69666.	2.5	25
39	MALT1 Small Molecule Inhibitors Specifically Suppress ABC-DLBCL InÂVitro and InÂVivo. <i>Cancer Cell</i> , 2012, 22, 812-824.	16.8	229
40	Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 1125-1132.	2.8	29
41	Epigenetic Profiling of Primary CLL Reveals Novel DNA Methylation-Based Clusters and Novel Mechanisms of Leukemogenesis. <i>Blood</i> , 2012, 120, 3877-3877.	1.4	0
42	IL10 Receptor a Is a Novel Therapeutic Target That Is Epigenetically Disregulated in Low Grade Lymphomas with Plasmacytic Differentiation.. <i>Blood</i> , 2012, 120, 2383-2383.	1.4	0
43	Three-Dimensional Reorganization of the Genome During B Cell Affinity Maturation. <i>Blood</i> , 2012, 120, 279-279.	1.4	0
44	DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation. <i>Blood</i> , 2011, 118, 3559-3569.	1.4	123
45	The Eph-Receptor A7 Is a Soluble Tumor Suppressor for Follicular Lymphoma. <i>Cell</i> , 2011, 147, 554-564.	28.9	151
46	Epigenetics and B-cell lymphoma. <i>Current Opinion in Hematology</i> , 2011, 18, 293-299.	2.5	60
47	SYK inhibition and response prediction in diffuse large B-cell lymphoma. <i>Blood</i> , 2011, 118, 6342-6352.	1.4	93
48	Chemosensitization of Diffuse Large B Cell Lymphoma by Demethylating Nucleoside Analogues. <i>Blood</i> , 2011, 118, 1617-1617.	1.4	0
49	Differential DNA Methylation of TUBB1 Correlates with Tissue-Specific Hî ² -1 Tubulin Expression. <i>Blood</i> , 2011, 118, 4796-4796.	1.4	0
50	Epigenetic Profiling of Primary DLBCLs Reveals Novel DNA Methylation-Based Clusters and New Underlying Mechanisms of Lymphomagenesis. <i>Blood</i> , 2011, 118, 556-556.	1.4	0
51	Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. <i>Blood</i> , 2010, 116, 1025-1034.	1.4	138
52	EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. <i>Blood</i> , 2010, 116, 5247-5255.	1.4	262
53	DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. <i>Blood</i> , 2010, 116, e81-e89.	1.4	138
54	Requirement for cyclin D3 in germinal center formation and function. <i>Cell Research</i> , 2010, 20, 631-646.	12.0	55

#	ARTICLE	IF	CITATIONS
55	HELP (HpaII Tiny Fragment Enrichment by Ligation-Mediated PCR) Assay for DNA Methylation Profiling of Primary Normal and Malignant B Lymphocytes. <i>Methods in Molecular Biology</i> , 2010, 632, 191-201.	0.9	26
56	BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. <i>Journal of Clinical Investigation</i> , 2010, 120, 4569-4582.	8.2	101
57	A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. <i>Nature Medicine</i> , 2009, 15, 1369-1376.	30.7	149
58	A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. <i>Blood</i> , 2009, 113, 3397-3405.	1.4	154
59	The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. <i>Blood</i> , 2009, 113, 5536-5548.	1.4	205
60	Genome-Wide Methylation Analysis of Primary Mantle Cell Lymphomas Identifies Novel Gene Targets for Epigenetic Drug Therapy.. <i>Blood</i> , 2009, 114, 673-673.	1.4	0
61	EZH2 Mediates DNA Methylation-Independent Epigenetic Silencing of a Germinal Center Specific Transcriptional Program That Contributes to Cellular Proliferation and Lymphomagenesis.. <i>Blood</i> , 2009, 114, 3465-3465.	1.4	2
62	ABC and GCB DLBCLs Display Unique Biologically Distinct and Clinically Relevant Epigenetic Signatures.. <i>Blood</i> , 2009, 114, 619-619.	1.4	10
63	Sequential Transcription Factor Targeting for Diffuse Large B-Cell Lymphomas. <i>Cancer Research</i> , 2008, 68, 3361-3369.	0.9	30
64	Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. <i>Blood</i> , 2008, 111, 1515-1523.	1.4	269
65	Epigenetic Determinants of Pathogenesis and Resistance to Proteasome Inhibition in Mantle Cell Lymphoma.. <i>Blood</i> , 2008, 112, 3373-3373.	1.4	8
66	Cyclin D3 Is Required for the Germinal Center Reaction. <i>Blood</i> , 2008, 112, 2580-2580.	1.4	0
67	BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. <i>Blood</i> , 2007, 110, 2067-2074.	1.4	117
68	DNA Methyltransferase 1 Contributes to Epigenetic Signatures and Biological Phenotype during Normal B-Cell Differentiation and Lymphomagenesis.. <i>Blood</i> , 2007, 110, 685-685.	1.4	1
69	Constitutively Activated STAT3 Promotes Cell Proliferation and Survival in the Activated B Cell Subtype of Diffuse Large B Cell Lymphomas.. <i>Blood</i> , 2007, 110, 1621-1621.	1.4	3
70	Nuclear and cytoplasmic AID in extrafollicular and germinal center B cells. <i>Blood</i> , 2006, 107, 3967-3975.	1.4	151
71	Stages of Germinal Center Transit Are Defined by B Cell Transcription Factor Coexpression and Relative Abundance. <i>Journal of Immunology</i> , 2006, 177, 6930-6939.	0.8	119
72	BCL6 Programs Lymphoma Cells for Survival and Differentiation through Distinct Biochemical Mechanisms, Both of Which Can Be Therapeutically Targeted.. <i>Blood</i> , 2006, 108, 225-225.	1.4	1

#	ARTICLE	IF	CITATIONS
73	BCL6 Regulates Diffuse Large B-Cell Lymphoma Cell Cycle and Apoptosis Checkpoints through Direct Repression of the p300 Histone Acetyl-Transferase.. Blood, 2006, 108, 1413-1413.	1.4	0
74	Identification of rare Epstein-Barr virus infected memory B cells and plasma cells in non-monomorphic post-transplant lymphoproliferative disorders and the signature of viral signaling. Haematologica, 2006, 91, 1313-20.	3.5	18
75	PRDM1/Blimp-1 is expressed in human B-lymphocytes committed to the plasma cell lineage. Journal of Pathology, 2005, 206, 76-86.	4.5	97
76	Protein Signature of LMP1 Signaling in PTLDs Identifies and Mimics Inter/Perifollicular CD30+ EBVâ B Blasts.. Blood, 2004, 104, 3251-3251.	1.4	0
77	Novel Relational Database for Tissue Microarray Analysis. Archives of Pathology and Laboratory Medicine, 2003, 127, 492-494.	2.5	24
78	A rare cause of nephrotic syndrome. American Journal of Kidney Diseases, 2002, 39, 892-895.	1.9	9
79	Leukemia translocation protein PLZF inhibits cell growth and expression of cyclin A. Oncogene, 1999, 18, 925-934.	5.9	177
80	The Promyelocytic Leukemia Zinc Finger Protein Affects Myeloid Cell Growth, Differentiation, and Apoptosis. Molecular and Cellular Biology, 1998, 18, 5533-5545.	2.3	164